Receptor binding sites of hypoglycemic sulfonylureas and related [(acylamino)alkyl]benzoic acids
- PMID: 6361256
- DOI: 10.1021/jm00367a016
Receptor binding sites of hypoglycemic sulfonylureas and related [(acylamino)alkyl]benzoic acids
Abstract
The blood glucose level lowering activity of [(acylamino)ethyl]benzoic acids, such as p-[2-(5-chloro-2-methoxy-benzamido)ethyl]benzoic acid (HB699, 2), is discussed in terms of binding at putative insulin-releasing receptor sites of pancreatic beta cells. The hypoglycemic potencies found for synthetic analogues of 2 indicate that high hypoglycemic activity is only found when a carboxyl group or a group that is readily oxidized to carboxyl in vivo, such as methyl, is attached to the aromatic ring of the phenethyl group. It is proposed that this carboxyl group is able to bind at the same receptor site as the SO2NHCONH group of the sulfonylurea drugs, such as tolbutamide (3). The role of the benzamide group in 2 was attributed to protein binding.
Similar articles
-
Control of insulin secretion by sulfonylureas, meglitinide and diazoxide in relation to their binding to the sulfonylurea receptor in pancreatic islets.Biochem Pharmacol. 1989 Apr 15;38(8):1217-29. doi: 10.1016/0006-2952(89)90327-4. Biochem Pharmacol. 1989. PMID: 2650685
-
[Pharmacological comparison between tolbutamide and two second generation hypoglycemic sulfonylureas (glibenclamide and glisoxepide)].Acta Diabetol Lat. 1973 Mar-Apr;10(2):261-82. Acta Diabetol Lat. 1973. PMID: 4200420 Italian. No abstract available.
-
Tissue specificity of sulfonylureas: studies on cloned cardiac and beta-cell K(ATP) channels.Diabetes. 1998 Sep;47(9):1412-8. doi: 10.2337/diabetes.47.9.1412. Diabetes. 1998. PMID: 9726229
-
Cellular loci of sulfonylurea actions.Diabetes Care. 1984 May-Jun;7 Suppl 1:67-71. Diabetes Care. 1984. PMID: 6376031 Review.
-
Sulfonylurea receptors and mechanism of sulfonylurea action.Exp Clin Endocrinol Diabetes. 1996;104(1):1-9. doi: 10.1055/s-0029-1211414. Exp Clin Endocrinol Diabetes. 1996. PMID: 8750563 Review.
Cited by
-
Structural requirements of sulphonylureas and analogues for interaction with sulphonylurea receptor subtypes.Br J Pharmacol. 1999 Sep;128(1):27-34. doi: 10.1038/sj.bjp.0702763. Br J Pharmacol. 1999. PMID: 10498831 Free PMC article.
-
Pharmacological rescue of trafficking-impaired ATP-sensitive potassium channels.Front Physiol. 2013 Dec 24;4:386. doi: 10.3389/fphys.2013.00386. Front Physiol. 2013. PMID: 24399968 Free PMC article. Review.
-
Mg(2+)-dependent inhibition of KATP by sulphonylureas in CRI-G1 insulin-secreting cells.Br J Pharmacol. 1994 Feb;111(2):632-40. doi: 10.1111/j.1476-5381.1994.tb14783.x. Br J Pharmacol. 1994. PMID: 8004407 Free PMC article.
-
Effects of sulphonylureas and diazoxide on insulin secretion and nucleotide-sensitive channels in an insulin-secreting cell line.Br J Pharmacol. 1988 Sep;95(1):83-94. doi: 10.1111/j.1476-5381.1988.tb16551.x. Br J Pharmacol. 1988. PMID: 3146398 Free PMC article.
-
Synthesis, characterization, antioxidant activity and DNA-binding studies of three rare earth (III) complexes with 1-(4-aminoantipyrine)-3-tosylurea ligand.J Fluoresc. 2009 Jan;19(1):63-72. doi: 10.1007/s10895-008-0381-7. Epub 2008 Jun 4. J Fluoresc. 2009. PMID: 18523879
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical